4D Molecular Therapeutics(FDMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FDMT 4D Molecular Therapeutics

Trading 10-22 13:40:17 EDT

12.37

-0.25

-2.02%

High13.12	Low12.23	Vol526.34K
Open12.60	D1 Closing12.62	Amplitude7.09%
Mkt Cap683.09M	Tradable Cap519.53M	Total Shares55.24M
T/O6.64M	T/O Rate1.25%	Tradable Shares42.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FDMT","market":"US","secType":"STK","nameCN":"4D Molecular Therapeutics","latestPrice":12.365,"timestamp":1792690810536,"preClose":12.62,"halted":0,"volume":526344,"delay":0,"changeRate":-0.020206022187004676,"floatShares":42016200,"shares":55244200,"eps":-2.758,"marketStatus":"Trading","change":-0.255,"latestTime":"10-22 13:40:17 EDT","open":12.6,"high":13.12,"low":12.225,"amount":6636678.864816,"amplitude":0.070919,"askPrice":12.38,"askSize":36,"bidPrice":12.35,"bidSize":249,"shortable":3,"etf":0,"ttmEps":-2.758,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1792699200000},"marketStatusCode":2,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":12.62,"preHourTrading":{"tag":"盘前","latestPrice":12.25,"preClose":12.62,"latestTime":"09:25 EDT","volume":5698,"amount":71211.045598,"timestamp":1792675551234,"change":-0.37,"changeRate":-0.029319,"amplitude":0.05626},"postHourTrading":{"tag":"盘后","latestPrice":12.62,"preClose":12.62,"latestTime":"19:30 EDT","volume":8440,"amount":106512.55,"timestamp":1792625406968,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.78904,"impliedVol":0.8974,"impliedVolPercentile":0.7052},"requestUrl":"/m/hq/s/FDMT/wiki","defaultTab":"wiki","newsList":[{"id":"2677915957","title":"Analysts’ Top Healthcare Picks: 4D Molecular Therapeutics (FDMT), Biodesix (BDSX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2677915957","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677915957?lang=en_us&edition=fundamental","pubTime":"2026-10-22 19:20","pubTimestamp":1792668010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on 4D Molecular Therapeutics (FDMT) and Biodesix (BDSX)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-4d-molecular-therapeutics-fdmt-biodesix-bdsx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-4d-molecular-therapeutics-fdmt-biodesix-bdsx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4137","XBI","BK4139","FDMT","LU0029874061.USD","XLV","BDSX","BK4588","LABU","HCSG","BK4196","BK4585","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677395438","title":"4D Molecular Therapeutics Price Target Maintained with a $36.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2677395438","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677395438?lang=en_us&edition=fundamental","pubTime":"2026-10-22 18:37","pubTimestamp":1792665420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FDMT/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677695983","title":"Analysts Conflicted on These Healthcare Names: Roivant Sciences (ROIV) and 4D Molecular Therapeutics (FDMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2677695983","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677695983?lang=en_us&edition=fundamental","pubTime":"2026-10-22 18:00","pubTimestamp":1792663231,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roivant Sciences (ROIV) and 4D Molecular Therapeutics (FDMT). Roi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-roivant-sciences-roiv-and-4d-molecular-therapeutics-fdmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-roivant-sciences-roiv-and-4d-molecular-therapeutics-fdmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4007","HCSG","XBI","LABU","XLV","ROIV","BK4139","BK4137","LU0128526141.USD","PTH","BK4585","BK4588","FDMT","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677058406","title":"4D Molecular Therapeutics Presents Two-Year 4D-150 Data Showing Reduced Injection Burden in Wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2677058406","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677058406?lang=en_us&edition=fundamental","pubTime":"2026-10-22 00:21","pubTimestamp":1792599719,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics Presents Two-Year 4D-150 Data Showing Reduced Injection Burden in Wet AMD4D Molecular Therapeutics presented stable two-year vision and retinal anatomy results for wet AMD th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nNDL9n6hq5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677661155","title":"4D Molecular Therapeutics Chief Legal Officer Scott Bizily Reports Sale of $20,993.40 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2677661155","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677661155?lang=en_us&edition=fundamental","pubTime":"2026-10-21 04:56","pubTimestamp":1792529814,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics Chief Legal Officer Scott Bizily Reports Sale of $20,993.40 in Common Shares4D Molecular Therapeutics Chief Legal Officer Scott Bizily sold 1,635 common shares at $12.84 each","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261020:nNDL3FKqFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"4D Molecular Therapeutics Chief Legal Officer Scott Bizily Reports Sale of $20,993.40 in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676696909","title":"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and 4D Molecular Therapeutics (FDMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2676696909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676696909?lang=en_us&edition=fundamental","pubTime":"2026-10-20 21:00","pubTimestamp":1792501210,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD) and 4D Molecular Therapeutics...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-4d-molecular-therapeutics-fdmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-4d-molecular-therapeutics-fdmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B7SZLL34.SGD","LU1057294990.SGD","BMED","BIB","SG9999015952.SGD","FDMT","GILD","BBH","LU0122379950.USD","BK4139","LU1839511570.USD","TBXU","LU1934455863.HKD","LU0320765992.SGD","LU1585245621.USD","BK4568","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU2087621335.USD","LU2089984988.USD","LU0234570918.USD","LU2468319806.SGD","LU1037948897.HKD","BK4550","BK4588","LU1934455194.USD","LU0128526141.USD","IBB","BK4532","XBI","LU0965509283.SGD","LU0058720904.USD","IBBQ","HCSG","BK4581","LABU","LU1023059063.AUD","LU0289739699.SGD","LU1571399168.USD","TMED","BK4566","LU0965509101.SGD","LU0114720955.EUR","SG9999015986.USD","LU0965508806.USD","MEDI","XLV","LU0859254822.USD","LU0109394709.USD","LU0861579265.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676751160","title":"4D Molecular Therapeutics Grants 260,000 Stock Options, 157,600 RSUs to 13 New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2676751160","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676751160?lang=en_us&edition=fundamental","pubTime":"2026-10-17 04:05","pubTimestamp":1792181131,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics grants 260,000 stock options, 157,600 RSUs to 13 new employees4D Molecular Therapeutics granted 13 new non-executive employees options to purchase 260,000 common shares on Oc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nNDL60hRvM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","SG9999014013.SGD","BCDF","IE00BN0W2W23.USD","BK4585","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","LU0314104364.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK4112","BK4588","LU2095319765.USD","SG9999014039.USD","FDMT","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675306083","title":"Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Pfizer (PFE) and Incyte (INCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675306083","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675306083?lang=en_us&edition=fundamental","pubTime":"2026-10-13 17:30","pubTimestamp":1791883837,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on 4D Molecular Therapeutics (FDMT), Pfizer (PFE) and...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-4d-molecular-therapeutics-fdmt-pfizer-pfe-and-incyte-incy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-4d-molecular-therapeutics-fdmt-pfizer-pfe-and-incyte-incy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0122379950.USD","SG9999002224.SGD","LU0868494617.USD","BK4533","BK4592","LU1894683264.USD","IE00BBT3K403.USD","BK4588","OZEM","IE0002270589.USD","BK4139","IE000M9KFDE8.USD","FDMT","LU2596442595.SGD","LU0306807586.USD","BK4599","BK4534","IE00B19Z3B42.SGD","LU0234572021.USD","LU0289739699.SGD","PFE","INCY","LU1066051498.USD","LU0058720904.USD","LU0985481810.HKD","LU1066053197.SGD","LU0456855351.SGD","IE00B3T34201.USD","SG9999011175.SGD","LU0170899867.USD","LU0321505868.SGD","IE00BLSP4452.SGD","SG9999002232.USD","SG9999001176.USD","BK4550","BK4585","LU1023059063.AUD","LU0225771236.USD","IDNA","LU0306806265.USD","LU0321505439.SGD","BK4581","BK4568","SGXZ57979304.SGD","BK4532","IE00B19Z3581.USD","SG9999013999.USD","IE00BLSP4239.USD","BK4007","SG9999001176.SGD","LU0225284248.USD","LU1883839398.USD","LU1057294990.SGD","LU1894683348.USD","SG9999003800.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673048079","title":"4D Molecular Therapeutics CEO David Kirn Disposes of USD 754,632 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048079","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048079?lang=en_us&edition=fundamental","pubTime":"2026-10-08 05:12","pubTimestamp":1791407547,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics CEO David Kirn disposes of USD 754,632 in common shares4D Molecular Therapeutics President and CEO David Kirn sold 58,333 shares on Oct. 5, 2026.Sales priced at USD 12.9215 a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL3QKmgS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"4D Molecular Therapeutics CEO David Kirn Disposes of USD 754,632 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673059502","title":"4D Molecular Therapeutics is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2673059502","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673059502?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:36","pubTimestamp":1791290160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FDMT/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673022037","title":"4D Molecular Therapeutics to Host Investor Day Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2673022037","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673022037?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:10","pubTimestamp":1791202222,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics to host investor day webcast4D Molecular Therapeutics will host an Investor Day in New York City on Oct. 21, 2026.Event starts at 10:30 a.m. ET, featuring company presentatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL1gvXDK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014005.SGD","SG9999014021.USD","BCDF","NDAQ","IE00BGHQF748.EUR","SG9999014013.SGD","LU2095319765.USD","BK4112","BK4585","BK4139","IE00BQXX3C00.GBP","BK4588","IE00BQXX3D17.EUR","SG9999014039.USD","IE00BKPKM429.USD","FDMT","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671214995","title":"4D Molecular Therapeutics Price Target Raised to $33.00/Share from $29.00 by B of a Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2671214995","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671214995?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:33","pubTimestamp":1790685180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FDMT/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"4D Molecular Therapeutics Price Target Raised to $33.00/Share from $29.00 by B of a Securities","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671215707","title":"4D Molecular price target raised to $33 from $29 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2671215707","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671215707?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:40","pubTimestamp":1790678435,"startTime":"0","endTime":"0","summary":"BofA raised the firm’s price target on 4D Molecular (FDMT) to $33 from $29 and keeps a Buy rating on the shares after the company reported two-year...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/4d-molecular-price-target-raised-to-33-from-29-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/4d-molecular-price-target-raised-to-33-from-29-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FDMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671290718","title":"Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Envista Holdings (NVST) and Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671290718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671290718?lang=en_us&edition=fundamental","pubTime":"2026-09-29 17:30","pubTimestamp":1790674217,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on 4D Molecular Therapeutics (FDMT), Envista Holdings...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-4d-molecular-therapeutics-fdmt-envista-holdings-nvst-and-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-4d-molecular-therapeutics-fdmt-envista-holdings-nvst-and-regeneron-regn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LU0130518102.USD","LU0823434740.USD","IBBQ","IE0034390439.USD","LU0648000940.SGD","LU2468319806.SGD","BK4581","LU2089984988.USD","TBXU","LU0289739699.SGD","BK4082","XBI","LU0128526141.USD","LU1917777945.USD","LU0130103400.USD","BBH","LU0029874061.USD","LU2362541513.USD","LU0882574055.USD","XLV","LU0058720904.USD","LU0889565916.HKD","LU0823434583.USD","LU2023250504.SGD","BK4139","LU0823416689.USD","BK4585","LU0114720955.EUR","LU2362540622.SGD","LU2362541273.HKD","BK4137","BK4588","NVST","LU1201861165.SGD","FDMT","HCSG","LU0320765992.SGD","LABU","LU0477156797.USD","IBB","LU0053666078.USD","LU2237438978.USD","IE00B19Z6F94.USD","REGN","LU2106854487.HKD","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670525606","title":"Ocular Therapeutix shares down 22% after 4D Molecular announces Phase 3 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2670525606","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670525606?lang=en_us&edition=fundamental","pubTime":"2026-09-28 23:20","pubTimestamp":1790608822,"startTime":"0","endTime":"0","summary":"Shares of Ocular Therapeutix (OCUL) are down 22% to $7.53 in morning trading after competitor 4D Molecular Therapeutics (FDMT) announced Phase 3 cl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ocular-therapeutix-shares-down-22-after-4d-molecular-announces-phase-3-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ocular-therapeutix-shares-down-22-after-4d-molecular-announces-phase-3-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OCUL","BK4007","FDMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670232640","title":"4D Molecular Therapeutics Enrolls First Patients in Phase 3 4sight Trial of 4D-150 for Diabetic Macular Edema","url":"https://stock-news.laohu8.com/highlight/detail?id=2670232640","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670232640?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:06","pubTimestamp":1790597217,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics enrolls first patients in Phase 3 4SIGHT trial of 4D-150 for diabetic macular edema4D Molecular Therapeutics enrolled the first patients in 4SIGHT, a global Phase 3 trial of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDLcfzTFG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","SG9999014005.SGD","BCDF","IE00BQXX3C00.GBP","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","LU2095319765.USD","FDMT","IE00BQXX3F31.USD","NDAQ","BK4112","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BK4139","BK4585","LU0314104364.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670323962","title":"4Dmt Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4Sight in Dme","url":"https://stock-news.laohu8.com/highlight/detail?id=2670323962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670323962?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:01","pubTimestamp":1790596903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45K0EJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FDMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670319232","title":"4D Molecular Therapeutics - First Patients Enrolled in 4Sight Phase 3 Trial for 4D-150 in Dme","url":"https://stock-news.laohu8.com/highlight/detail?id=2670319232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670319232?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:01","pubTimestamp":1790596903,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45K0EJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FDMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669758120","title":"4D Molecular Therapeutics Chief Legal Officer Scott Bizily Disposes of USD 22,317.75 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2669758120","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669758120?lang=en_us&edition=fundamental","pubTime":"2026-09-23 06:44","pubTimestamp":1790117050,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics Chief Legal Officer Scott Bizily disposes of USD 22,317.75 in common sharesChief Legal Officer Scott Bizily exercised stock options in 4D Molecular Therapeutics on Sep. 16, 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDLtcrz3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"4D Molecular Therapeutics Chief Legal Officer Scott Bizily Disposes of USD 22,317.75 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668936816","title":"4D Molecular Therapeutics CEO David Kirn Disposes of 58,333 Common Shares Worth $810,105.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2668936816","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668936816?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:14","pubTimestamp":1789593282,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics CEO David Kirn disposes of 58,333 common shares worth $810,105.1David Kirn, president, CEO, sold 58,333 shares of 4D Molecular Therapeutics common stock on Sept. 14, 2026.Sal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL1btS2R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"4D Molecular Therapeutics CEO David Kirn Disposes of 58,333 Common Shares Worth $810,105.1","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.4dmoleculartherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0344},{"period":"1month","weight":-0.1719},{"period":"3month","weight":0.2158},{"period":"6month","weight":0.3426},{"period":"1year","weight":0.1228},{"period":"ytd","weight":0.6827}],"compareEarnings":[{"period":"1week","weight":0.0045},{"period":"1month","weight":-0.0005},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.0829},{"period":"1year","weight":0.1516},{"period":"ytd","weight":0.1337}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.04533},{"month":2,"riseRate":0.333333,"avgChangeRate":0.049284},{"month":3,"riseRate":0.5,"avgChangeRate":-0.025952},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.08755},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.077313},{"month":6,"riseRate":0.333333,"avgChangeRate":0.008847},{"month":7,"riseRate":0.666667,"avgChangeRate":0.03588},{"month":8,"riseRate":0.5,"avgChangeRate":0.092617},{"month":9,"riseRate":0.5,"avgChangeRate":-0.027878},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.04033},{"month":11,"riseRate":0.6,"avgChangeRate":0.385036},{"month":12,"riseRate":0.2,"avgChangeRate":-0.036146}],"exchange":"NASDAQ","name":"4D Molecular Therapeutics","nameEN":"4D Molecular Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"4D Molecular Therapeutics(FDMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest 4D Molecular Therapeutics(FDMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"4D Molecular Therapeutics,FDMT,4D Molecular Therapeutics股票,4D Molecular Therapeutics股票老虎,4D Molecular Therapeutics股票老虎国际,4D Molecular Therapeutics行情,4D Molecular Therapeutics股票行情,4D Molecular Therapeutics股价,4D Molecular Therapeutics股市,4D Molecular Therapeutics股票价格,4D Molecular Therapeutics股票交易,4D Molecular Therapeutics股票购买,4D Molecular Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"4D Molecular Therapeutics(FDMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest 4D Molecular Therapeutics(FDMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}